A recent survey by the Pistoia Alliance reveals that only 1% of life sciences professionals perceive artificial intelligence (AI) as valuable in wet lab environments. Despite 30% of organizations claiming to have implemented enterprise-wide AI, a significant 69% lack metrics to demonstrate its impact on cost reduction or timeline efficiency.
This finding aligns with data from a Deloitte survey, which indicated that while 22% of life sciences leaders have successfully scaled AI, only 9% reported substantial returns on their investments. The Pistoia Alliance gathered this information during their European conference in London, featuring representatives from major organizations such as Roche, AstraZeneca, and the FDA.
One of the main discussions at the conference centered on the disconnect between AI investment and its perceived value. According to Becky Upton, president of The Pistoia Alliance, successful AI implementation relies heavily on data quality and change management, with 59% of respondents emphasizing the need for better data accessibility. Furthermore, the benefits of AI appear to vary across the research and development (R&D) lifecycle, with regulatory teams reporting the most significant advantages.
Ammara Gafoor from Thoughtworks noted that while AI can enhance the speed of the R&D pipeline, its current application is often fragmented, limiting overall effectiveness. The industry must find ways to integrate AI efforts across teams to achieve broader gains. However, there are promising developments on the horizon, such as collaborations that leverage advanced AI tools, which could enhance efficiency in wet lab settings.